DaVita Management
Management criteria checks 3/4
DaVita's CEO is Javier Rodriguez, appointed in Jun 2019, has a tenure of 5.5 years. total yearly compensation is $6.71M, comprised of 21% salary and 79% bonuses, including company stock and options. directly owns 1.02% of the company’s shares, worth $130.32M. The average tenure of the management team and the board of directors is 5.2 years and 4.4 years respectively.
Key information
Javier Rodriguez
Chief executive officer
US$6.7m
Total compensation
| CEO salary percentage | 21.0% |
| CEO tenure | 5.5yrs |
| CEO ownership | 1.0% |
| Management average tenure | 5.2yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Market Still Lacking Some Conviction On DaVita Inc. (NYSE:DVA)
Dec 15
DaVita's (NYSE:DVA) Returns On Capital Are Heading Higher
Nov 30DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation
Nov 14Is DaVita Inc. (NYSE:DVA) Potentially Undervalued?
Nov 13Is DaVita (NYSE:DVA) A Risky Investment?
Oct 29An Intrinsic Calculation For DaVita Inc. (NYSE:DVA) Suggests It's 47% Undervalued
Sep 16DaVita Inc.'s (NYSE:DVA) Shares Lagging The Market But So Is The Business
Sep 01DaVita (NYSE:DVA) Has A Pretty Healthy Balance Sheet
Jul 02Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?
Jun 19Are DaVita Inc. (NYSE:DVA) Investors Paying Above The Intrinsic Value?
Jun 04Returns On Capital At DaVita (NYSE:DVA) Have Hit The Brakes
May 22DaVita Stock Is A Hold As It Expands In Latin America
Mar 18Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost
Mar 13Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?
Mar 04DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 16Is DaVita (NYSE:DVA) Using Too Much Debt?
Feb 08DaVita: Assessing After The Rally
Dec 29DaVita: Simple And Compelling After Sell-Off
Oct 26DaVita: Continued Economic Hurdles, Market Expectations May Be Correct
Oct 05DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold
Jul 21DaVita HealthCare Partners Q4 2022 Earnings Preview
Feb 21Moon Capital - DaVita: A Recession-Resistant Cash Generating Machine
Feb 08DaVita: Shares Still Appear Cheap After Outlook Cut, Technicals Suggest Caution
Dec 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$828m |
| Jun 30 2024 | n/a | n/a | US$860m |
| Mar 31 2024 | n/a | n/a | US$816m |
| Dec 31 2023 | US$7m | US$1m | US$692m |
| Sep 30 2023 | n/a | n/a | US$596m |
| Jun 30 2023 | n/a | n/a | US$454m |
| Mar 31 2023 | n/a | n/a | US$500m |
| Dec 31 2022 | US$3m | US$1m | US$547m |
| Sep 30 2022 | n/a | n/a | US$680m |
| Jun 30 2022 | n/a | n/a | US$834m |
| Mar 31 2022 | n/a | n/a | US$903m |
| Dec 31 2021 | US$3m | US$1m | US$978m |
| Sep 30 2021 | n/a | n/a | US$984m |
| Jun 30 2021 | n/a | n/a | US$883m |
| Mar 31 2021 | n/a | n/a | US$791m |
| Dec 31 2020 | US$73m | US$1m | US$783m |
| Sep 30 2020 | n/a | n/a | US$832m |
| Jun 30 2020 | n/a | n/a | US$824m |
| Mar 31 2020 | n/a | n/a | US$816m |
| Dec 31 2019 | US$17m | US$1m | US$705m |
| Sep 30 2019 | n/a | n/a | US$623m |
| Jun 30 2019 | n/a | n/a | US$548m |
| Mar 31 2019 | n/a | n/a | US$551m |
| Dec 31 2018 | US$8m | US$900k | US$616m |
| Sep 30 2018 | n/a | n/a | US$617m |
| Jun 30 2018 | n/a | n/a | US$698m |
| Mar 31 2018 | n/a | n/a | US$652m |
| Dec 31 2017 | US$8m | US$900k | US$909m |
Compensation vs Market: Javier's total compensation ($USD6.71M) is below average for companies of similar size in the US market ($USD12.84M).
Compensation vs Earnings: Javier's compensation has increased by more than 20% in the past year.
CEO
Javier Rodriguez (53 yo)
5.5yrs
Tenure
US$6,712,328
Compensation
Mr. Javier J. Rodriguez serves as an Independent Director at Gilead Sciences, Inc. since June 15, 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rod...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.5yrs | US$6.71m | 1.02% $ 130.3m | |
| CFO & Treasurer | 7.8yrs | US$6.87m | 0.11% $ 14.4m | |
| Chief Legal & Public Affairs Officer | 8.6yrs | US$5.61m | 0.073% $ 9.3m | |
| Chief Compliance Officer | 6.8yrs | US$2.73m | 0.015% $ 1.9m | |
| Chief Operating Officer | less than a year | no data | 0.0073% $ 936.2k | |
| Group VP & Chief Accounting Officer | 1.3yrs | no data | no data | |
| Chief Information Officer | less than a year | no data | no data | |
| Group Vice President of Investor Relations | no data | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Chief Transformation Officer of U.S. Kidney Care Business | no data | no data | no data | |
| Chief Medical Officer of Kidney Care | 4.8yrs | no data | no data | |
| Chief Medical Officer of DaVita International | 6.3yrs | no data | no data |
5.2yrs
Average Tenure
55yo
Average Age
Experienced Management: DVA's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.5yrs | US$6.71m | 1.02% $ 130.3m | |
| Director | 17.8yrs | US$322.46k | 0.032% $ 4.1m | |
| Independent Director | 9.2yrs | US$384.96k | 0.015% $ 1.9m | |
| Independent Director | 8.4yrs | US$374.96k | 0.015% $ 1.9m | |
| Independent Director | 1.4yrs | US$106.86k | 0.0022% $ 284.4k | |
| Independent Chair | 15.6yrs | US$497.46k | 0.030% $ 3.9m | |
| Independent Director | less than a year | no data | 0.00075% $ 95.7k | |
| Independent Director | 2.3yrs | US$334.96k | 0.0044% $ 565.0k | |
| Independent Director | 2.6yrs | US$364.96k | 0.0055% $ 706.6k | |
| Independent Director | 3.3yrs | US$355.89k | 0.0070% $ 895.4k |
4.4yrs
Average Tenure
61.5yo
Average Age
Experienced Board: DVA's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 05:51 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DaVita Inc. is covered by 37 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephan Gasteyger | Atlantic Equities LLP |
| Brian Williams | Avondale Partners |
| Matthew Gillmor | Baird |